Completed PHASE1 INTERVENTIONAL NCT00000739

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Sponsor: Jacobus Pharmaceutical

Conditions HIV Infections Pneumonia, Pneumocystis Carinii

Interventions Dapsone

Updated 7 times since 2017 Last updated: Oct 27, 2021 Completion: Jun 30, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infections and Pneumonia, Pneumocystis Carinii, this trial is completed. The trial is conducted by Jacobus Pharmaceutical and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jacobus Pharmaceutical
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Bayamón, Puerto Rico , Boston, United States , Brooklyn, United States , Charleston, United States , Chicago, United States , Cleveland, United States , Detroit, United States , Durham, United States and 24 more locations